Theranostic imaging and multimodal photodynamic therapy and immunotherapy using the mTOR signaling pathway.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 09 2023
02 09 2023
Historique:
received:
01
07
2022
accepted:
11
08
2023
medline:
5
9
2023
pubmed:
3
9
2023
entrez:
2
9
2023
Statut:
epublish
Résumé
Tumor metastases are considered the leading cause of cancer-associated deaths. While clinically applied drugs have demonstrated to efficiently remove the primary tumor, metastases remain poorly accessible. To overcome this limitation, herein, the development of a theranostic nanomaterial by incorporating a chromophore for imaging and a photosensitizer for treatment of metastatic tumor sites is presented. The mechanism of action reveals that the nanoparticles are able to intervene by local generation of cellular damage through photodynamic therapy as well as by systemic induction of an immune response by immunotherapy upon inhibition of the mTOR signaling pathway which is of crucial importance for tumor onset, progression and metastatic spreading. The nanomaterial is able to strongly reduce the volume of the primary tumor as well as eradicates tumor metastases in a metastatic breast cancer and a multi-drug resistant patient-derived hepatocellular carcinoma models in female mice.
Identifiants
pubmed: 37660174
doi: 10.1038/s41467-023-40826-5
pii: 10.1038/s41467-023-40826-5
pmc: PMC10475087
doi:
Substances chimiques
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5350Informations de copyright
© 2023. Springer Nature Limited.
Références
Nanophotonics. 2021 Sep;10(12):3199-3214
pubmed: 37485044
Nat Rev Cancer. 2003 May;3(5):380-7
pubmed: 12724736
Drug Resist Updat. 2008 Jun;11(3):63-76
pubmed: 18440854
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
J Intern Med. 2013 Aug;274(2):113-26
pubmed: 23844915
Mol Oncol. 2020 Dec;14(12):2994-3006
pubmed: 33179413
Angew Chem Int Ed Engl. 2019 Oct 1;58(40):14334-14340
pubmed: 31386250
Chin J Cancer. 2017 Apr 3;36(1):38
pubmed: 28372569
Chem Soc Rev. 2013 Jan 7;42(1):77-88
pubmed: 23014776
Cancer Res. 2000 May 1;60(9):2497-503
pubmed: 10811131
Adv Drug Deliv Rev. 2008 Dec 14;60(15):1627-37
pubmed: 18930086
J Immunother Cancer. 2019 Dec 16;7(1):350
pubmed: 31842994
Chem Rev. 2015 Feb 25;115(4):1990-2042
pubmed: 25602130
Oncogene. 2022 Apr;41(17):2431-2443
pubmed: 35279705
Chem Soc Rev. 2016 Nov 7;45(22):6250-6269
pubmed: 27333329
Dalton Trans. 2018 Aug 21;47(31):10330-10343
pubmed: 29978870
Nano Lett. 2020 Mar 11;20(3):1928-1933
pubmed: 32073871
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
Angew Chem Int Ed Engl. 2022 Jan 26;61(5):e202112236
pubmed: 34748690
Adv Sci (Weinh). 2022 May;9(16):e2200732
pubmed: 35343113
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
Cell Death Dis. 2020 Nov 26;11(11):1013
pubmed: 33243969
Chem Rev. 2021 Nov 10;121(21):13454-13619
pubmed: 34582186
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6700-5
pubmed: 23569259
Nat Rev Cancer. 2003 Jun;3(6):453-8
pubmed: 12778135
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nanoscale Horiz. 2020 Jun 2;5(6):999-1015
pubmed: 32364553
Chem Soc Rev. 2020 Feb 21;49(4):1041-1056
pubmed: 31845688
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
ACS Nano. 2021 Mar 23;15(3):5428-5438
pubmed: 33689300
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Chem Soc Rev. 2022 Feb 21;51(4):1212-1233
pubmed: 35099487
Breast Cancer Res Treat. 2011 Jul;128(1):7-21
pubmed: 21499686
Photochem Photobiol. 2009 Sep-Oct;85(5):1053-74
pubmed: 19682322
Nat Commun. 2020 Dec 7;11(1):6299
pubmed: 33288764
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
ACS Nano. 2018 May 22;12(5):4886-4893
pubmed: 29727164
Org Lett. 2008 Dec 4;10(23):5421-4
pubmed: 19006394
J Biol Chem. 1996 Jan 5;271(1):83-8
pubmed: 8550629
Nat Rev Cancer. 2005 Aug;5(8):591-602
pubmed: 16056258
ACS Appl Mater Interfaces. 2020 Dec 9;12(49):54433-54444
pubmed: 33238711
J Am Chem Soc. 2011 Jan 19;133(2):252-61
pubmed: 21162575
Trends Biotechnol. 2008 Nov;26(11):612-21
pubmed: 18804298
Cancer Lett. 2008 Jul 18;266(1):53-9
pubmed: 18362051
Angew Chem Int Ed Engl. 2022 May 9;61(20):e202201486
pubmed: 35212437
J Biol Inorg Chem. 2020 Dec;25(8):1035-1050
pubmed: 33146771
Nanoscale. 2012 Jan 21;4(2):330-42
pubmed: 22134683
Lasers Med Sci. 2009 Mar;24(2):259-68
pubmed: 18247081
Adv Mater. 2017 May;29(19):
pubmed: 28295684
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
Int J Mol Sci. 2013 Dec 05;14(12):23774-90
pubmed: 24317436
Gene. 2018 Oct 5;673:130-133
pubmed: 29908282
ACS Nano. 2019 Aug 27;13(8):8648-8658
pubmed: 31328920
Chem Rev. 2019 Jan 23;119(2):797-828
pubmed: 30295467
Nat Rev Clin Oncol. 2020 Nov;17(11):657-674
pubmed: 32699309
ACS Appl Mater Interfaces. 2017 Sep 27;9(38):32475-32481
pubmed: 28875695
ACS Appl Mater Interfaces. 2019 May 1;11(17):15426-15435
pubmed: 30945838
Biomaterials. 2016 Apr;84:13-24
pubmed: 26803408
Angew Chem Int Ed Engl. 2023 May 15;62(21):e202300662
pubmed: 36807420
J Porphyr Phthalocyanines. 2020 Nov-Dec;24(11n12):1320-1360
pubmed: 37425217
Photochem Photobiol Sci. 2019 Feb 13;18(2):495-504
pubmed: 30644946
Chem Sci. 2020 Jan 30;11(10):2657-2663
pubmed: 34084324
Biomaterials. 2021 Aug;275:120979
pubmed: 34166910
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Int J Mol Sci. 2019 Feb 11;20(3):
pubmed: 30754640